Advertisement

ASCO 2023: Osimertinib for Patients With EGFR-Mutated NSCLC
Posted: 06/20/2023 | By: Melissa E. Fryman, MS

At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Herbst et al presented final overall survival results of the ADAURA trial, which evaluated the efficacy of osimertinib among patients with completely resected; EGFR-mutated; stage IB, II, or IIIA non–small cell lung cancer (NSCLC) (Abstract LBA3).

Question 1 of 5

Osimertinib is a third-generation, central nervous system active EGFR tyrosine kinase inhibitor (TKI) that potently and selectively inhibits:

Choose 1

A
EGFR-TKI sensitizing mutations
B
EGFR T790M resistance mutations
C
PACC resistance mutations
D
EGFR-TKI sensitizing and EFR T790M resistance mutations

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage